Eisai and Merck halt liver cancer trial after missing survival goal
Tweet Send to a Friend
Eisai Co. and Merck & Co. (NYSE: MRK) announced they will close their Phase 3 LEAP-012 trial after the combination ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
